

3rd Quarter Fiscal Year 2024 Business Update



May 30th, 2024



Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

Luxembourg. May 30, 2024 – Moolec Science SA (NASDAQ: MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.

The main highlights of Moolec's business update are as follows:

- **Piggy Sooy™ Product | Soybean Platform:** Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.
- **Safflower Platform:** GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.
- **Financial highlight:** Normalized revenues and other income up ~\$1.3MYoY given consolidation of soy-protein ingredient business. R&D, Admin and other expenses of \$2.3M increased 68% YoY mainly due to non-cash items. Operational cash utilization this quarter of ~\$2.6M includes ~\$1.4M allocated to lower accounts payable

"These past few months mark a significant milestone in Moolec's journey, showcasing our relentless pursuit to deliver results. Our progress on Piggy Sooy™ with the USDA-APHIS regulatory RSR approval, in addition to the starting of our GLASO™ commercial production streams are pivotal achievements that underscore our unwavering commitment to nutritional and sustainable solutions. I am thrilled to witness just the beginning of the fruits of our labor and am grateful for the continued and unwavering dedication of our team," expressed Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

José López Lecube, Chief Financial Officer for the company stated, *"We are very pleased with our team's consistent milestones delivery as we are addressing meaningful market opportunities. We remain confident in our disciplined approach to spending while preserving an adequate cash position and balance sheet to fund the business. I want to extend my congratulations to our team for the exceptional USDA-APHIS regulatory RSR approval, a major achievement for our long-term business plan execution."*

Conference Call

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar.

To access the call, please use the following information:

- Date: Thursday, May 30, 2024
- Time: 08:30 AM Eastern Time (US and Canada)
- Link to join the webinar:
<https://icrinc.zoom.us/j/91289208286?pwd=Rm9SS0hlRzN6d0lWdU1od3lrZTBxdz09>
- One tap mobile: +13017158592,,91289208286#,,,,*888246# US
- Dial In: +1 301 715 8592 | Webinar ID: 912 8920 8286, Passcode: 888246
- International numbers available:
<https://icrinc.zoom.us/u/aid5QyFr4>

Please connect 5 minutes prior to the start time to register and join.

A recording of the call and the pdf version of the presentation will be available after the conclusion of the live event via Moolec's [Investor Relations website](#).

About Moolec Science SA

Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Moolec’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

1. Scientific and Operational Progress

a. Piggy Sooy™ Product | Soybean Platform

On April 18, 2024, Moolec's Piggy Sooy™ soybean seeds received USDA-APHIS Regulatory Status Review approval. This approval indicates that the USDA-APHIS RSR has determined that Moolec's genetically engineered soybean, accumulating animal meat protein, is unlikely to pose an increased plant pest risk relative to non-engineered soybeans. Therefore, it is not subject to the APHIS regulation that governs the movement of organisms modified or produced through genetic engineering (as described in 7 CFR part 340). This furthermore signifies a huge milestone as the first approval of its kind among plant-based animal proteins.

Moolec has developed a patentable soybean platform under the trademark Piggy Sooy™ for the expression of highly valuable proteins in seeds of economically important crops such as soybeans. The project started with 550 T0 transgenic events that were screened for the presence of the desired meat protein via PCR tests and yield metrics. As a result of the analysis, we have narrowed down the number of events where 140 T2 events have been selected. In Piggy Sooy™ the detection of the desired protein has been optimized and subsequently quantified for each of the transgenic events. Results for T2 show porcine myoglobin expression levels up to 26.6% TSP (total soluble protein) and up to 20.4% TSP for T3. We expect these expression values to keep stabilizing with the advancement of generations and identification of truly homozygous lines.

Chief Science Officer Amit Dhingra oversees the plant molecular farming platform at Moolec Science. Moolec set up a fully owned operational Plant Molecular Biology Laboratory in Texas A&M Bioscience Business Accelerator facility in College Station, TX, where lab work began in September 2023. The laboratory is currently 100% operational and Moolab's Team is responsible for all protein expression assessments for Piggy Sooy™.

With the approval from USDA-APHIS RSR, we are moving forward with field trials of fourth generation (T4) seeds. T4 soybean seeds were greenhouse harvested in April and are ready to be shipped for field trials, which have been planted in mid-May 2024.

As previously stated, these high levels of heterologous protein expression have not been previously documented in scientific literature for soybean seeds nor for an animal protein in plants. Not only does Moolec intend to use the Piggy Sooy™ platform for innovative food ingredients, but also to eventually address the protein requirements in other industries such as pharma, cosmetics, research, diagnostic reagents, and other food industries. Interest in the use of

Piggy Soy™ technology extending to other industries is demonstrated in the non-binding Memorandum of Understanding (MOU) agreement that Moolec signed with Mediprogen, a South-Korean plant biotech venture company which aims to produce valuable cosmetic and pharmaceutical proteins from biotech soybean seeds. Mediprogen had reached out to Moolec proactively after the announcement of Moolec's patent filing and high level of expression results.

b. Safflower Platform

In February 2024, Moolec's 2023 safflower production was used to perform a trial production of GLASO™ at the toll processor facility aimed to optimize process and production.

In late April the planting of safflower GLA commenced and was completed in early May. Moolec successfully contracted growers for a total of 600 acres for crushing purposes. In addition, a 60-acre field was planted for seed production. ~200 to 400 tones of safflower is expected to be produced in this campaign.

Also, two patents were granted in April 2024 related to the production of chymosin in safflower seeds (SPC2 technology). These patents are related to the technology and process developed to increase expression levels of the bovine enzyme in safflower seeds.

2. Financial overview

This period, the Company has transitioned to reporting year-over-year from quarter-over-quarter to enhance meaningful insight for the purposes of long-term financial analysis and to align with the industry's standard practice.

Review of consolidated results

Company reported figures are presented applying IAS 29 accounting for its Argentinean subsidiary. The following table shows “As reported” in conjunction with “Excluding IAS 29” results in order to provide more context for the evolution of the underlying business.

In thousands of US Dollars	As reported		Normalized	
	Q3 FY2023	Q3 FY2024	Q3 FY2023	Q3 FY2024
Revenue	-	2,109.9	-	1,175.6
Other income	-	184.7	-	75.2
Cost of sales	-	(2,018.1)	-	(1,027.4)

Unaudited Financial Statements Highlights Q3FY24 vs. Q3FY23

a) Statement of Operations

- Revenues and other income as reported amounted to \$2,294.6 thousand during Q3FY24. Excluding the impact of IAS 29, revenues and other income increased from nil to \$1,250.8 thousand during Q3FY24 compared to Q3FY23, given the consolidation of soy-protein ingredient business in April 2023.
- Cost of sales as reported amounted to \$2,018.1 thousand during Q3FY24. Excluding the impact of IAS 29, cost of sales increased from nil to \$1,027.4 thousand during Q3FY24 compared to Q3FY23, given the consolidation of soy-protein ingredient business in April 2023.
- R&D expenses of \$447.6 thousand during Q3FY24 decreased \$128.5 thousand compared to Q3FY23 primarily driven by the different stages and nature of the projects, as we continue to successfully execute the overall business strategy.
- Administrative expenses of \$1,611.7 thousand during Q3FY24 increased 112% compared to Q3FY23 mainly due to non-cash items such as amortization and depreciation charges and equity incentives

as well as the consolidation of soy-protein ingredient business together.

b) Statement of Financial Position

- As of March 31, 2024, there was an increase of \$1,901.1 thousand or 8% in our total assets arising to \$25,952.3 thousand compared to FY2023.
- Current assets, which mainly comprise cash and cash equivalents, inventories and trade receivables increased by 24% compared to FY2023, mainly driven by the increase in cash and cash equivalents as a result of cash inflows in exchange of issuing convertible notes.
- Non-current assets slightly increased by 3% amounting to \$19,339.4 thousand since FY2023 mainly related to the accrual of interest receivable and partially offset by the effect of changes in foreign currency over intangibles denominated in Argentine Pesos.
- Current liabilities decreased by \$4,777.5 thousand or 38% amounting to \$7,821.6 thousand compared to FY2023, mainly due to the decrease in accounts payables and to a lesser extent to a decrease in the fair value of our warrant liabilities and other current liabilities.
- Non-current liabilities increased by \$10,145.3 thousand amounting to \$11,491.4 thousand since FY2023 mainly related to the issuance of convertible notes and classified as financial liabilities.

c) Statement of Cash Flows

- During the quarter ended March 31, 2024, we raised \$5.0 million in cash through convertible notes issued in October 2023. As of March 31, 2024, and June 30, 2023, cash and cash equivalents totaled \$4,252.0 thousand and \$2,527.7 thousand, respectively.
- In the nine months period ended in March 2024, we used \$8,288.0 thousand of net cash in operating activities mainly related to cover listing costs, research and development and other selling and administrative costs.
- We have generated net cash through financing activities during the nine months ended March 31, 2024, amounting to \$9,509.6 thousand mainly due to the issuance of convertible notes and partially offset by payments of principal and interest of outstanding financial debt.

ANNEX: Statement of Operations, Statement of Financial Position and Cash Flow Statement

Consolidated Statements of Operations

	For the three months ended March 31, 2024	For the three months ended March 31, 2023	Change	For the nine months ended March 31, 2024	For the nine months ended March 31, 2023	Change
	(In thousands of U.S. dollars, unless otherwise noted)		(%)	(In thousands of U.S. dollars, unless otherwise noted)		(%)
Continuing operations						
Revenue	2,109.9	-	N/A	4,102.0	-	N/A
Cost of sales	(2,018.1)	-	N/A	(3,557.8)	-	N/A
Other income	184.7	-	N/A	395.5	-	N/A
Research and development expense	(447.6)	(576.1)	(22%)	(1,351.4)	(980.6)	38%
Marketing expense	(228.0)	(14.4)	1,483%	(460.9)	(54.2)	750%
Administrative expense	(1,611.7)	(761.0)	112%	(5,160.5)	(1,486.4)	247%
Other operating expense	(31.0)	(28.2)	10%	(69.8)	(49.3)	42%
Loss from operations	(2,041.8)	(1,379.7)	48%	(6,102.9)	(2,570.5)	137%
Financial cost	(358.8)	-	N/A	(555.5)	-	N/A
Other financial results	1,125.5	86.1	1,207%	1,557.3	(230.4)	(776%)

Transaction expenses	-	934.9	(100%)	-	(3,535.0)	(100%)
Share based payment cost of listing of shares	-	-	-	-	(42,705.1)	(100%)
Loss before Income tax	(1,275.1)	(358.7)	255%	(5,101.1)	(49,041.0)	(90%)
Income tax	(127.0)	-	N/A	324.3	-	N/A
Loss of the period	(1,402.1)	(358.7)	291%	(4,776.8)	(49,041.0)	(90%)
Foreign exchange differences on translation of foreign operations	847.5	-	N/A	(66.1)	-	N/A
Total comprehensive loss for the period	(554.6)	(358.7)	55%	(4,842.9)	(49,041.0)	(90%)
Basic and diluted loss per share	(0.04)	(0.01)	289%	(0.13)	(1.47)	91%

Condensed consolidated Statements of Financial Position

	As of March 31, 2024	As of June 30, 2023	Change
(In thousands of U.S. dollars, unless otherwise noted)			(%)
Current assets	6,612.9	5,331.8	24%
Non-current assets	19,339.4	18,719.4	3%

	As of March 31, 2024	As of June 30, 2023	Change
Total assets	25,952.3	24,051.2	8%
Equity	6,639.3	10,106.0	(34%)
Current liabilities	7,821.6	12,599.1	(38%)
Non-current liabilities	11,491.4	1,346.1	754%
Total liabilities	19,313.0	13,945.2	38%
Total liabilities and equity	25,952.3	24,051.2	8%

Condensed consolidated Statements of Cash Flows

	For the nine months ended March 31, 2024	For the nine months ended March 31, 2023	Change
(In thousands of U.S. dollars, unless otherwise noted)			
Net cash (used) / generated in operating activities	(8,288.0)	(4,846.7)	71%
Net cash (used) / generated from investing activities	158.9	(148.7)	(207%)
Net cash (used) / generated from financing activities	9,509.6	10,000.0	(5%)

Net (decrease) / increase in cash and cash equivalents	1,380.5	5,004.6	(72%)
--	---------	---------	-------

Cash and cash equivalents at beginning of the period	2,527.7	1,081.8	134%
--	---------	---------	------

Effect of exchange rate changes and inflation on cash equivalents	343.8	133.6	157%
---	-------	-------	------

Cash and cash equivalents at end of the period	4,252.0	6,220.0	(32%)
--	---------	---------	-------

Contacts:

- Investor Relations inquiries: ir@moolecscience.com | MoolecIR@icrinc.com
- Press & Media inquiries: comms@moolecscience.com